IndustryCompany release

CorMedix agrees to buy substantially all of Heron Therapeutics' assets, adding four marketed drugs

🇺🇸 CorMedix Inc. (CRMD) · Tue 10 Nov 2026

The deal brings ZYNRELEF, APONVIE, CINVANTI and SUSTOL under CorMedix, with about $150 million in trailing-12-month net revenue and a Pharmakon term loan backing the purchase.

CorMedix Inc. announced on 9 November 2026 that it has signed a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics. The company published its announcement the following day.

The assets include four marketed products: ZYNRELEF, APONVIE, CINVANTI and SUSTOL. The agreement also covers a development agreement under which one new drug application (NDA) is pending at the US Food and Drug Administration (FDA). The summary of the announcement does not name the product or give a decision date for that NDA.

CorMedix says the acquired products generate roughly $150 million in net revenue over the trailing 12 months. It expects annual cost synergies of $45 million to $60 million by the end of 2027.

Closing is conditional on approval by Heron stockholders and on regulatory clearances. The transaction is supported by a term loan facility from Pharmakon. The material available does not give the purchase price, the loan size or an expected closing date.

What it means for your team

  • Regulatory teams at both companies should expect marketing authorisation holder and NDA ownership transfers once the deal closes, subject to the conditions set out in the agreement.
  • Pharmacovigilance and quality functions will need to plan for the handover of safety databases, supplier and manufacturing arrangements and product-complaint handling for the four marketed products.
  • Market-access teams should watch for any change in commercial contacts or contracting arrangements for the acute-care and oncology-support products, though none has been announced.

Company's press release (SEC filing): CorMedix Inc. ↗

Article written by VigiEye from the official source (CorMedix Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →